北海道大学薬学部　大学院薬学研究院
臨床薬剤学研究室

 

PUBLICATIONS/ 論文

 

HOME > 論文（研究業績）
 
学会賞・学術賞

2024 /2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003

2024年

  • Tamaki R, Noshiro K, Furugen A, Nishimura A, Asano H, Watari H, Kobayashi M, Umazume T. Breast milk concentrations of acetaminophen and diclofenac - unexpectedly high mammary transfer of the general-purpose drug acetaminophen. BMC Pregnancy Childbirth. 2024 Jan 29;24(1):90. doi: 10.1186/s12884-024-06287-4. PMID: 38287321; PMCID: PMC10826108.
  • Sakuma T, Mukai Y, Yamaguchi A, Suganuma Y, Okamoto K, Furugen A, Narumi K, Ishikawa S, Saito Y, Kobayashi M. Monocarboxylate Transporters 1 and 2 Are Responsible for L-Lactate Uptake in Differentiated Human Neuroblastoma SH-SY5Y Cells. Biol Pharm Bull. 2024;47(4):764-770. doi: 10.1248/bpb.b23-00860. PMID: 38569835.

2023年

  • Ueda H, Narumi K, Asano S, Saito Y, Furugen A, Kobayashi M. Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors. Expert Opin Drug Saf. 2023 Dec 14. doi: 10.1080/14740338.2023.2295976. Epub ahead of print. PMID: 38097359.
  • Ueda Y, Furugen A, Kobayashi M, Sato Y, Ueda Y, Hayashi A, Goto T, Kimura S, Narugami M, Nakakubo S, Nakajima M, Egawa K, Okamoto T, Manabe A, Shiraishi H. Use of lacosamide for focal epilepsy in a child with kidney failure undergoing peritoneal dialysis. Brain Dev. 2023 Oct 30:S0387-7604(23)00156-0. doi: 10.1016/j.braindev.2023.10.003. Epub ahead of print. PMID: 37914622.
  • Yamaguchi A, Mukai Y, Sakuma T, Suganuma Y, Furugen A, Narumi K, Kobayashi M. Molecular characteristic analysis of single-nucleotide polymorphisms in SLC16A9/hMCT9. Life Sci. 2023 Dec 1;334:122205. doi: 10.1016/j.lfs.2023.122205. PMID: 37879602.
  • Mori A, Kato I, Narumi K, Takekuma Y, Kashiwagi H, Sato Y, Sugawara M, Kobayashi M. Quantitative analysis of communication changes in online medication counseling ―Using the Roter Interaction Analysis System. Res Social Adm Pharm. 2023. doi: 10.1016j.sapharm.2023.10.001
  • Yamagami A, Narumi K, Saito Y, Furugen A, Imai S, Kitagawa Y, Ohiro Y, Takagi R, Takekuma Y, Sugawara M, Kobayashi M. Development of a risk prediction model for surgical site infection after lower third molar surgery. Oral Dis. 2023 Sep 27. doi: 10.1111/odi.14747. Epub ahead of print. PMID: 37759366.
  • Furugen A, Nishimura A, Umazume T, Ishikawa H, Narumi K, Kobayashi M. Simple and validated method to quantify lacosamide in human breast milk and plasma using UPLC/MS/MS and its application to estimate drug transfer into breast milk. J Pharm Health Care Sci. 2023 Sep 1;9(1):26. doi: 10.1186/s40780-023-00295-w. PMID: 37653499; PMCID: PMC10472561.
  • Yamamoto Y, Narumi K, Yamagishi N, Nishi T, Ito T, Iseki K, Kobayashi M, Kanai Y. Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. Front Pharmacol. 2023 Jul 31;14:1197743. doi: 10.3389/fphar.2023.1197743. PMID: 37583904; PMCID: PMC10424117.
  • Ohyama N, Furugen A, Sawada R, Aoyagi R, Nishimura A, Umazume T, Narumi K, Kobayashi M. Effects of valproic acid on syncytialization in human placental trophoblast cell lines. Toxicol Appl Pharmacol. 2023 Sep 1;474:116611. doi: 10.1016/j.taap.2023.116611. PMID: 37385477.
  • Yamaguchi A, Mukai Y, Sakuma T, Furugen A, Narumi K, Kobayashi M. Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4. Anticancer Res. 2023 Jul;43(7):3015-3022. doi: 10.21873/anticanres.16472. PMID: 37351987.
  • Yasuda G, Kubota A, Okamoto K, Narumi K, Furugen A, Kato I, Mori A, Saito Y, Satoh T, Takahashi-Suzuki N, Iseki K, Kobayashi M. Association between α-defensin 5 and the expression and function of P-glycoprotein in differentiated intestinal Caco-2 cells. Biopharm Drug Dispos. 2023 Jun 5. doi: 10.1002/bdd.2367. PMID: 37277970.
  • Nadai T, Narumi K, Mukai Y, Ueda H, Furugen A, Saito Y, Kobayashi M. 5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells. Anticancer Res. 2023 Mar;43(3):1113-1120. doi: 10.21873/anticanres.16256. PMID: 36854517.
  • Yamaguchi A, Mukai Y, Sakuma T, Narumi K, Furugen A, Yamada Y, Kobayashi M. Monocarboxylate transporter 4 involves in energy metabolism and drug sensitivity in hypoxia. Sci Rep. 2023 Jan 27;13(1):1501. doi: 10.1038/s41598-023-28558-4. PMID: 36707650.

2022年

  • Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, Shimizu Y, Dosaka-Akita H, Sugawara M, Kobayashi M. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. J Cancer Res Clin Oncol. 2023 Apr;149(4):1659-1666. doi: 10.1007/s00432-022-04425-z. PMID: 36346501.
  • Mukai Y, Yamaguchi A, Sakuma T, Nadai T, Furugen A, Narumi K, Kobayashi M. Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line. Biopharm Drug Dispos. 2022 Oct;43(5):183-191. doi: 10.1002/bdd.2329. PMID: 36104287.
  • Ueda H, Narumi K, Furugen A, Saito Y, Kobayashi M. The rs35217482 (T755I) single-nucleotide polymorphism in aldehyde oxidase-1 attenuates protein dimer formation and reduces the rates of phthalazine metabolism. Drug Metab Dispos. 2022 Jul 16:DMD-AR-2022-000902. doi: 10.1124/dmd.122.000902. Epub ahead of print. PMID: 35842227.
  • Mori A, Kato I, Kashiwagi H, Imai S, Narumi K, Sato Y, Furugen A, Yamada Y, Kobayashi M. [Development of an Online Role-play-based Medical Interview Training Method for Fourth-year Pharmacy Students]. Yakugaku Zasshi. 2022;142(6):661-674. Japanese. doi: 10.1248/yakushi.21-00233. PMID: 35650086.
  • Koishikawa M, Furugen A, Ohyama N, Narumi K, Ishikawa S, Kobayashi M. Uptake of antiepileptic drugs in forskolin-induced differentiated BeWo cells: alteration of gabapentin transport. Xenobiotica. 2022 Apr;52(4):405-412. doi: 10.1080/00498254.2022.2085635. Epub 2022 Jun 16. PMID: 35642749.
  • Yamagami A, Narumi K, Saito Y, Furugen A, Imai S, Kitagawa Y, Ohiro Y, Takagi R, Takekuma Y, Sugawara M, Kobayashi M. Evaluation of the strategies to reduce third-generation oral cephalosporins in dentistry at a Japanese academic hospital: An interrupted time series analysis. J Clin Pharm Ther. 2022 Jul;47(7):1010-1019. doi: 10.1111/jcpt.13636. Epub 2022 Mar 7. PMID: 35253939.
  • Kubota A, Terasaki M, Takai R, Kobayashi M, Muromoto R, Kojima H. 5-Aminosalicylic Acid, A Weak Agonist for Aryl Hydrocarbon Receptor That Induces Splenic Regulatory T Cells. Pharmacology. 2022;107(1-2):28-34. doi: 10.1159/000520404. Epub 2021 Dec 16. PMID: 34915497.

2021年

  • Okamoto K, Ueda H, Saito Y, Narumi K, Furugen A, Kobayashi M. Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity. Drug Metab Pharmacokinet. 2021 Dec;41:100417. doi: 10.1016/j.dmpk.2021.100417. Epub 2021 Aug 16. PMID: 34619549.
  • Nadai T, Narumi K, Furugen A, Saito Y, Iseki K, Kobayashi M. Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells. Biol Pharm Bull. 2021;44(9):1247-1253. doi: 10.1248/bpb.b21-00030. PMID: 34471053.
  • Takahashi Y, Narumi K, Nadai T, Ueda H, Yamamura T, Furugen A, Kobayashi M. In vitro and in vivo evaluation of organic anion-transporting polypeptide 2B1-mediated pharmacokinetic interactions by apple polyphenols. Xenobiotica. 2021 Nov;51(11):1318-1325. doi: 10.1080/00498254.2021.1969480. Epub 2021 Aug 24. PMID: 34396892.
  • Okamoto K, Kitaichi F, Saito Y, Ueda H, Narumi K, Furugen A, Kobayashi M. Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats. Eur J Pharmacol. 2021 Oct 15;909:174395. doi: 10.1016/j.ejphar.2021.174395. Epub 2021 Jul 29. PMID: 34332922.
  • Furugen A, Kanno Y, Ohyama N, Kurosawa Y, Jinno N, Narumi K, Iseki K, Kobayashi M. Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats. Drug Metab Pharmacokinet. 2021 Oct;40:100409. doi: 10.1016/j.dmpk.2021.100409. Epub 2021 Jun 7. PMID: 34293696. 
  • Okamoto K, Saito Y, Ueda H, Narumi K, Furugen A, Kobayashi M. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells. Biopharm Drug Dispos. 2021 Sep;42(8):389-392. doi: 10.1002/bdd.2298. Epub 2021 Jul 29. PMID: 34287957.
  • Yamaguchi A, Saito Y, Okamoto K, Narumi K, Furugen A, Takekuma Y, Sugawara M, Kobayashi M. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis. Support Care Cancer. 2021 Dec;29(12):7747-7753. doi: 10.1007/s00520-021-06359-7. Epub 2021 Jun 23. PMID: 34164739.
  • Yamamura T, Narumi K, Ohata T, Satoh H, Mori T, Furugen A, Kobayashi M, Iseki K. Characterization of deoxyribonucleoside transport mediated by concentrative nucleoside transporters. Biochem Biophys Res Commun. 2021 Jun 18;558:120-125. doi: 10.1016/j.bbrc.2021.04.075. Epub 2021 Apr 25. PMID: 33910126.
  • Kobayashi M, Narumi K, Furugen A, Iseki K. Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). Pharmacol Ther. 2021 Oct;226:107862. doi: 10.1016/j.pharmthera.2021.107862. Epub 2021 Apr 22. PMID: 33894276.
  • Okamoto K, Saito Y, Narumi K, Furugen A, Iseki K, Kobayashi M. Anticancer effects of non-steroidal anti-inflammatory drugs against cancer cells and cancer stem cells. Toxicol In Vitro. 2021 Aug;74:105155. doi: 10.1016/j.tiv.2021.105155. Epub 2021 Mar 27. PMID: 33785417.
  • Yasuda G, Kobayashi M, Kubota A, Narumi K, Furugen A, Saito Y, Satoh T, Suzuki N, Iseki K. Analysis of α-Defensin 5 Secretion in Differentiated Caco-2 Cells: Comparison of Cell Bank Origin. Biol Pharm Bull. 2021;44(2):275-278. doi: 10.1248/bpb.b20-00644. Erratum in: Biol Pharm Bull. 2022;45(4):552. PMID: 33518681.
  • Nishimura A, Furugen A, Umazume T, Kitamura S, Soma M, Noshiro K, Takekuma Y, Sugawara M, Iseki K, Kobayashi M. Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose. Breastfeed Med. 2021 May;16(5):424-431. doi: 10.1089/bfm.2020.0259. Epub 2021 Jan 15. PMID: 33449825.

2020年

  • Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Suzuki Y, Miyoshi H, Nakamura A, Atsumi T, Iseki K.The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes.Drug Metab Pharmacokinet. 2020 Dec 14;37:100376.doi:10.1016/j.dmpk.2020.100376.
  • 古堅彩子. 妊娠・授乳期の適切な薬物治療に向けた母体–胎児・乳児間の物質移行に関する研究. Yakugaku Zasshi. 2020;140(10):1199-1206. 
  • Ishikawa S, Kobayashi M, Hashimoto N, Mikami H, Tanimura A, Narumi K, Furugen A, Kusumi I, Iseki K. Association between N-desmethylclozapine and clozapine-induced sialorrhea: Involvement of increased nocturnal salivary secretion via muscarinic receptors by N-desmethylclozapine. J Pharmacol Exp Ther. 2020 Aug 29;JPET-AR-2020-000164. doi: 10.1124/jpet.120.000164.
  • Yamaguchi A, Narumi K, Furugen A, Iseki K, Kobayashi M. Identification of the essential extracellular aspartic acids conserved in human monocarboxylate transporters 1, 2, and 4. Biochem Biophys Res Commun. 2020 Sep 3;529(4):1061-1065. doi: 10.1016/j.bbrc.2020.06.068.
  • Okamoto K, Saito Y, Narumi K, Furugen A, Iseki K, Kobayashi M. Different mechanisms of cisplatin resistance development in human lung cancer cells.Biochem Biophys Res Commun. 2020 Oct 1;530(4):745-750. doi: 10.1016/j.bbrc.2020.07.040. 
  • Okamoto K, Saito Y, Narumi K, Furugen A, Iseki K, Kobayashi M. Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. Eur J Pharmacol. 2020 Jul 26;173339. doi: 10.1016/j.ejphar.2020.173339. 
  • Ueda H, Narumi K, Sato Y, Furugen A, Kobayashi M, Iseki K.Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. Pharmacol Rep. 2020 Jul 15. doi: 10.1007/s43440-020-00130-1.
  • Jinno N, Furugen A, Kurosawa Y, Kanno Y, Narumi K, Kobayashi M, Iseki K. Effects of single and repetitive valproic acid administration on the gene expression of placental transporters in pregnant rats: An analysis by gestational period. Reprod Toxicol. 2020 May 11;96:47-56. doi: 10.1016/j.reprotox.2020.04.077. 
  • Hasegawa N, Furugen A, Ono K, Koishikawa M, Miyazawa Y, Nishimura A, Umazume T, Narumi K, Kobayashi M, Iseki K. Cellular uptake properties of lamotrigine in human placental cell lines: Investigation of involvement of organic cation transporters (SLC22A1-5). Drug Metab Pharmacokinet. 2020 Jun;35(3):266-273. doi: 10.1016/j.dmpk.2020.01.005. 
  • Okamoto K, Saito Y, Narumi K, Furugen A, Iseki K, Kobayashi M. Non-steroidal Anti-inflammatory Drugs Are a Risk Factor for Cisplatin-induced Nephrotoxicity: A Meta-analysis of Retrospective Studies. Anticancer Res. 2020 Mar;40(3):1747-1751. doi: 10.21873/anticanres.14128.

2019年

  • Futagi Y, Narumi K, Furugen A, Kobayashi M, Iseki K. Molecular characterization of the orphan transporter SLC16A9, an extracellular pH- and Na+-sensitive creatine transporter. Biochem Biophys Res Commun. 2019 Nov 26. doi: 10.1016/j.bbrc.2019.11.137.
  • Higuchi I, Kimura Y, Kobayashi M, Narumi K, Furugen A, Miyoshi H, Nakamura A, Yamada T, Atsumi T, Iseki K. Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. Drug Metab Pharmacokinet. 2019 Oct 17.  doi: 10.1016/j.dmpk.2019.10.001.
  • Narumi K, Ohata T, Horiuchi Y, Satoh H, Furugen A, Kobayashi M, Iseki K. Mutual role of ecto-5'-nucleotidase/CD73 and concentrative nucleoside transporter 3 in the intestinal uptake of dAMP. PLoS One. 2019 Oct 21;14(10):e0223892. doi: 10.1371/journal.pone.0223892.
  • Yamaguchi A, Futagi Y, Kobayashi M, Narumi K, Furugen A, Iseki K. Extracellular lysine 38 plays a crucial role in pH-dependent transport via human monocarboxylate transporter 1. Biochim Biophys Acta Biomembr. 2019 Oct 5. doi: 10.1016/j.bbamem.2019.183068.
  • Kondo A, Narumi K, Okuhara K, Takahashi Y, Furugen A, Kobayashi M, Iseki K. Black tea extract and theaflavin derivatives affect the pharmacokinetics of rosuvastatin by modulating organic anion transporting polypeptide (OATP) 2B1 activity. Biopharm Drug Dispos. 2019 Aug 10. doi: 10.1002/bdd.2202.
  • Futagi Y, Kobayashi M, Narumi K, Furugen A, Iseki K. Homology modeling and site-directed mutagenesis identify amino acid residues underlying the substrate selection mechanism of human monocarboxylate transporters 1 (hMCT1) and 4 (hMCT4). Cell Mol Life Sci. 2019 May 17. doi: 10.1007/s00018-019-03151-z.
  • Ono K, Furugen A, Kurosawa Y, Jinno N, Narumi K, Kobayashi M, Iseki K. Analysis of the effects of polyunsaturated fatty acids on transporter expressions using a PCR array: Induction of xCT/SLC7A11 in human placental BeWo cells. Placenta. 2019 Jan;75:34-41.
  • Furugen A, Nishimura A, Kobayashi M, Umazume T, Narumi K, Iseki K. Quantification of eight benzodiazepines in human breastmilk and plasma by liquid-liquid extraction and liquid-chromatography tandem mass spectrometry: Application to evaluation of alprazolam transfer into breastmilk. J Pharm Biomed Anal. 2019 May 10;168:83-93.

2018年

  • Futagi Y, Kobayashi M, Narumi K, Furugen A, Iseki K. Identification of a selective inhibitor of human monocarboxylate transporter 4. Biochem Biophys Res Commun. 2018 Jan 1;495(1):427-432.
  • Ideno M, Kobayashi M, Sasaki S, Futagi Y, Narumi K, Furugen A, Iseki K. Involvement of monocarboxylate transporter 1 (SLC16A1) in the uptake of l-lactate in human astrocytes. Life Sci. 2018 Jan 1;192:110-114.
  • Kurosawa Y, Furugen A, Nishimura A, Narumi K, Kobayashi M, Iseki K. Evaluation of the effects of antiepileptic drugs on folic acid uptake by human placental choriocarcinoma cells. Toxicol In Vitro. 2018 Apr;48:104-110.
  • Kubota A, Kobayashi M, Sarashina S, Takeno R, Okamoto K, Narumi K, Furugen A, Suzuki Y, Takahashi N, Iseki K. Reishi mushroom Ganoderma lucidum Modulates IgA production and alpha-defensin expression in the rat small intestine. J Ethnopharmacol. 2018 Mar 25;214:240-243.
  • Ishiguro Y, Kobayashi M, Ideno M, Narumi K, Furugen A, Iseki K. Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity. Int J Pharm. 2018 Nov 15;551(1-2):97-102.
  • Kimura Y, Kobayashi M, Asari M, Higuchi I, Narumi K, Furugen A, Iseki K. Genetic variations in the monocarboxylate transporter genes (SLC16A1, SLC16A3, and SLC16A11) in the Japanese population. Drug Metab Pharmacokinet.
  • Imai S, Yamada T, Kasashi K, Niinuma Y, Kobayashi M, Iseki K. Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: A data mining analysis using a decision tree model. J Eval Clin Pract. 2019 Feb;25(1):163-170.
  • Ishiguro Y, Furugen A, Narumi K, Nishimura A, Hirano T, Kobayashi M, Iseki K. Valproic acid transport in the choriocarcinoma placenta cell line JEG-3 proceeds independently of the proton-dependent transporters MCT1 and MCT4. Drug Metab Pharmacokinet. 2018 Dec;33(6):270-274.
  • Kubota A, Kobayashi M, Sarashina S, Takeno R, Yasuda G, Narumi K, Furugen A, Takahashi-Suzuki N, Iseki K. Gamma-Aminobutyric Acid (GABA) Attenuates Ischemia Reperfusion-Induced Alterations in Intestinal Immunity. Biol Pharm Bull. 2018;41(12):1874-1878.

2017年

  • Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer.25(2), 481-487, 2017.
  • Furugen A, Ishiguro Y, Kobayashi M, Narumi K, Nishimura A, Hirano T, Iseki K. Involvement of l-type amino acid transporter 1 in the transport of gabapentin into human placental choriocarcinoma cells. Reprod Toxicol.67, 48-55, 2017.
  • Kaneko C, Ogura J, Sasaki S, Okamoto K, Kobayashi M, Kuwayama K, Narumi K, Iseki K. Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation. Biochim Biophys Acta.1861(3), 559-566, 2017.
  • Kondo A, Narumi K, Ogura J, Sasaki A, Yabe K, Kobayashi T, Furugen A, Kobayashi M, Iseki K. Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin. Drug Metab. Pharmacokinet. 32(2), 145-150, 2017.
  • Kobayashi T, Koizumi T, Kobayashi M, Ogura J, Horiuchi Y, Kimura Y, Kondo A, Furugen A, Narumi K, Takahashi N, Iseki K. Insulin stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1 in the human intestinal cell line Caco-2. Drug Metab. Pharmacokinet. 32(2), 157-163, 2017.
  • Imai S, Yamada T, Kasashi K, Kobayashi M, Iseki K. Usefulness of a decision tree model for the analysis of adverse drug reactions: Evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure. Journal of evaluation in clinical practice. 2017.
  • Narumi K, Sato Y, Kobayashi M, Furugen A, Kasashi K, Yamada T, Teshima T, Iseki K. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Biopharmaceutics & drug disposition. 2017.
  • Saito Y, Okamoto K, Kobayashi M, Narumi K, Furugen A, Yamada T, Iseki K. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration. Life sciences. 2017.
  • Saito Y, Okamoto K, Kobayashi M, Narumi K, Yamada T, Iseki K. Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters. European journal of pharmacology. 811, 191-198, 2017.
  • Futagi Y, Sasaki S, Kobayashi M, Narumi K, Furugen A, Iseki K. The flexible cytoplasmic loop 3 contributes to the substrate affinity of human monocarboxylate transporters. Biochimica et biophysica acta. 1859(10), 1790-1795, 2017.
  • Imai S, Yamada T, Ishiguro N, Miyamoto T, Kagami K, Tomiyama N, Niinuma Y, Nagasaki D, Suzuki K, Yamagami A, Kasashi K, Kobayashi M, Iseki K. Validating the Effectiveness of Switching the Vancomycin TDM Analysis Software Based on the Predictive Accuracy. Yakugaku Zasshi. 2017;137(9):1185-1192.

2016年

  • Ideno S, Sasaki S, Kobayashi M, Futagi Y, Narumi K, Iseki K. Influence of high glucose state on bromopyruvate-induced cytotoxity by human colon cancer cell lines. Drug Metab. Pharmacokinet.31(1), 67-72, 2016.
  • Kikutani Y, Kobayashi M, Konishi T, Sasaki S, Narumi K, Furugen A, Takahashi N, Iseki K. Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity.  J Pharm Sci. 105(4) 1544-9, 2016.
  • Sasaki S, Futagi Y, Ideno M, Kobayashi M, Narumi K, Furugen A, Iseki K. Effect of diclofenac on SLC16A3/MCT4 by the Caco-2 cell line. Drug Metab Pharmacokinet.31(3), 218-223, 2016.
  • Sasaki S, Futagi Y, Ideno M, Kobayashi M, Narumi K, Furugen A, Iseki K. Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol.788, 248-254, 2016.
  • Narumi K, Kobayashi M, Kondo A, Furugen A, Yamada T, Takahashi N, Iseki K. Characterization of loxoprofen transport in Caco-2 cells: the involvement of a proton-dependent transport system in the intestinal transport of loxoprofen. Biopharm Drug Dispos.37(8), 447-455, 2016.
     

2015年

  • 今井俊吾，山田武宏，西村あや子，沖　洋充，熊井正貴，宮本剛典，笠師久美子，井関　健. 2種のバンコマイシンTDM解析ソフトの予測性に関する比較検討. 医薬品情報学, 16(4), 169-178, 2015.
  • Sasaki S, Futagi Y, Kobayashi M, Ogura J,  Iseki K. Functional Characterization of 5-Oxoproline Transport via SLC16A1/MCT1. J Biol Chem, 290(4), 2303-2311, 2015.
  • Ohya H, Shibayama Y, Ogura J, Narumi K, Kobayashi M, Iseki K. Regorafenib Is Transported by the Organic Anion Transporter 1B1 and the Multidrug Resistance Protein 2. Biol Pharm Bull, 38(4), 582-586, 2015.
  • Shibayama Y, Kondo T, Ohya H, Fujisawa S, Teshima T, Iseki K. Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep, 33(5), 2176-2182, 2015.
  • Sasaki S, Kobayashi M, Futagi Y, Ogura J, Yamaguchi H, Iseki K. Involvement of histidine residue His382 in pH regulation of SLC16A3 activity. PLoS One, 10, e0122738, 2015.
  • Wada T, Kobayashi M, Ono Y, Mizugaki A, Katabami K, Maekawa K, Miyamoto D, Yanagida Y, Hayakawa M, Sawamura A, Iseki K, Gando S. Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration. J Intensive Care, 3(1), 22, 2015.
  • Ogura J, Kuwayama K, Sasaki S, Kaneko C, Koizumi T, Yabe K, Tsujimoto T, Takeno R, Takaya A, Kobayashi M, Yamaguchi H, Iseki K. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen. Biochem Pharmacol. 97(1), 89-98, 2015.
  • Yamada T, Ishiguro N, Oku K, Higuchi I, Nakagawa I, Noguchi A, Yasuda S, Fukumoto T, Iwasaki S, Akizawa K, Furugen A, Yamaguchi H, Iseki K. Successful Colistin Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection Using a Rapid Method for Determination of Colistin in Plasma: Usefulness of Therapeutic Drug Monitoring. Biol Pharm Bull, 38(9), 1430-3, 2015.
  • Furugen A, Kobayashi M, Nishimura A, Takamura S, Narumi K, Yamada T, Iseki K. Quantification of new antiepileptic drugs by liquid chromatography/electrospray ionization tandem mass spectrometry and its application to cellular uptake experiment using human placental choriocarcinoma BeWo cells. J Chromatogr B Analyt Technol Biomed Life Sci, 1002, 228-233, 2015.
  • Kobayashi M. Role of Monocarboxylate Transporter in Statin-induced Cytotoxicity. Yakugaku Zasshi. 135(11), 1227-33. 2015.

2014年

  • 山田武宏，白鳥聡一，杉田純一，藤本勝也　，豊嶋宗徳，福元達也、岩崎澄央，秋沢宏次，鳴海克哉，石黒信久，井関　健. チゲサイクリンとコリスチンの併用が奏功した多剤耐性アシネトバクター・バウマニによるカテーテル関連血流感染症の１例. 日本化学療法学会雑誌, (62)4, 501-505, 2014.
  • Ogura J, Koizumi T, Segawa M, Yabe K, Kuwayama K, Sasaki S, Kaneko C, Tsujimoto T, Kobayashi M, Yamaguchi H, Iseki K. Quercetin-3-rhamnoglucoside (rutin) stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1. Biopharm Drug Dispos, 35(3), 173-182, 2014.
  • Watanabe M, Kobayashi M, Ogura J, Takahashi N, Yamaguchi H, Iseki K. Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats. J Pharm Pharm Sci, 17(1), 25-33, 2014.
  • Takahashi N, Kobayashi M, Ogura J, Yamaguchi H, Satoh T, Watanabe K, Iseki K. Immunoprotective effect of epigallocatechin-3-gallate on oral anticancer drug-induced α-defensin reduction in Caco-2 cells. Biol Pharm Bull, 37(3), 490-492, 2014.
  • Terada Y, Ogura J, Tsujimoto T, Kuwayama K, Koizumi T, Sasaki S, Maruyama H, Kobayashi M, Yamaguchi H, Iseki K. Intestinal P-glycoprotein expression is multimodally regulated by intestinal ischemia-reperfusion. J Pharm Pharm Sci, 17(2), 266-276, 2014.
  • Tanaka N, Yamaguchi H, Furugen A, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. Quantification of intracellular and extracellular eicosapentaenoic acid-derived 3-series prostanoids by liquid chromatography/electrospray ionization tandem mass spectrometry. Prostaglandins Leukot Essent Fatty Acids, 91(3), 61-71, 2014.
  • Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, Takahashi T, Horita S, Dosaka-Akita H, Iseki K. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Medicine, 3(6), 1544-1552, 2014.
  • Yamaguchi H, Miyamori K, Sato T, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. Quantification of intracellular and extracellular digoxin and ouabain by liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 972, 73-80, 2014.

2013年

  • Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci, 102(3), 1086-1094, 2013.
  • Ito H, Yamaguchi H, Fujikawa A, Shiida N, Tanaka N, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. Quantification of intact carboplatin in human plasma ultrafitrates using hydrophilic interaction liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 917-918, 18-23, 2013.
  • Saito Y, Kasashi K, Yoshiyama Y, Fukushima N, Kawagishi T, Yamada T, Iseki K. Survey on the Attitudes of Pharmacy Students in Japan toward Doping and Supplement Intake. Biol Pharm Bull, 36(2), 305-10, 2013.
  • Segawa M, Ogura J, Seki S, Itagaki S, Takahashi N, Kobayashi M, Hirano T, Yamaguchi H, Iseki K. Rapid stimulating effect of the antiarrhythmic agent amiodarone on absorption of organic anion compounds. Drug Metab Pharmacokinet, 28(3), 178-186, 2013.
  • Yamaguchi H, Fujikawa A, Ito H, Tanaka N, Furugen A, Miyamori K, Takahashi N, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma using column-switching liquid chromatography/tandem mass spectrometry. Biomed Chromatogr, 27(4), 539-544, 2013.
  • Kobayashi M, Gouda K, Chisaki I, Asada K, Ogura J, Takahashi N, Konishi T, Koshida Y, Sasaki S, Yamaguchi H, Iseki K. Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: Involvement of SREBP-mediated gene regulation. Int J Pharm, 452(1-2), 36-41, 2013.
  • Sasaki S, Kobayashi M, Futagi Y, Ogura J, Yamaguchi H, Takahashi N, Iseki K. Crucial Residue Involved in L-Lactate Recognition by Human Monocarboxylate Transporter 4 (hMCT4). PLoS One.8, e67690, 2013.
  • Otake S, Kobayashi M, Narumi K, Sasaki S, Kikutani Y, Furugen A, Watanabe M, Takahashi N, Ogura J, Yamaguchi H, Iseki K.  Regulation of the expression and activity of glucose and lactic acid metabolism- related genes by protein kinase C (PKC) in skeletal muscle cells. Biol Pharm Bull, 36(9), 1435-1439, 2013.
  • Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob AgentsChemother, 57(12), 6319-6324, 2013.
  • Furugen A, Yamaguchi H, Tanaka N, Shiida N, Ogura J, Kobayashi M, Iseki K. Contribution of multidrug resistance-associated proteins (MRPs) to the release of prostanoids from A549 cells. Prostaglandins Other Lipid Mediat, 2013.
  • 斉藤由起子,久保田康生,西村あや子,笠師久美子,山田武宏,篠原信雄,近藤覚也，井関　健. 尿路上皮がんにおけるＧＣ療法とＧＣｂ療法の血液毒生の比較. 医療薬学(39)7, 406-412, 2013.
  • 藤村拓也,久保田康生,今田愛也,相馬まゆ子,佐々木洋一,笠師久美子,山田武宏,小松嘉人,井関　健. パクリタキセルを含むがん化学療法における抹消神経障害に対するプレガバリンの有用性についての検討. 医療薬学, (39)9, 546-551, 2013.
  • 吉田和幸，林　鉱司，神田麻香，井関　健. 散薬調剤における薬剤師の不安全行動についてのアンケート調査 日本病院薬剤師会雑誌, (65)10, 1193-1196, 2013.
  • Maruyama H, Ogura J, Fujikawa A, Terada Y, Tsujimoto T, Koizumi T, Kuwayama K, Kobayashi M, Yamaguchi H, Iseki K. Intestinal ischemia-reperfusion suppresses biliary excretion of hepatic organic anion transporting polypeptides substrate. J Pharm Pharm Sci, 16(5), 722-731, 2013.
  • Tsujimoto T, Ogura J, Kuwayama K, Koizumi T, Sasaki S, Terada Y, Kobayashi M, Yamaguchi H, Iseki K. Effect of oxidative stress on expression and function of human and rat organic anion transporting polypeptides in the liver. Int J Pharm, 458(2), 262–271, 2013.

2012年

  • 長田貴之,柴山良彦,熊井正貴,山田武宏,笠師久美子,倉本倫之介,州崎真吾,赤澤　茂､真栄田浩行,坂下智博,折館伸彦,本間昭宏,福田　諭,菅原　満,井関　健. オピオイドによる難治性の嘔気とめまいに対してヒスタミンH1受容体拮抗薬とペロスピロンの併用が有効であった２症例. 医療薬学, (38)1, 51-55, 2012.
  • Sato Y, Suzuki R, Kobayashi M, Itagaki S, Hirano T, Noda T, Mizuno S, Sugawara M, Iseki K. Involvement of Cholesterol Membrane Transporter Niemann-PickC1-Like 1 in the Intestinal Absorption of Lutein. J Pharm Pharm Sci, 15(2), 256-264, 2012.
  • Narumi K, Kobayashi M, Otake S, Furugen A, Takahashi N, Ogura J, Itagaki S, Hirano T, Yamaguchi H, Iseki K. Regulation of human monocarboxylate transporter 4 in skeletal muscle cells: the role of protein kinase C (PKC). Int J Pharm, 30, 428(1-2), 25-32, 2012.
  • Yamaguchi H, Fujikawa A, Ito H, Tanaka N, Furugen A, Miyamori K, Takahashi N, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. A rapid and sensitive LC/ESI–MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study Journal of Chromatography Analyt.Technol. Biomed. Life Sci, (893/894), 157-161, 2012.
  • Ogura J, Kuwayama K, Takaya A, Terada Y, Tsujimoto T, Koizumi T, Maruyama H, Fujikawa A, Takahashi N, Kobayashi M, Itagaki S, Hirano T, Yamaguchi H, Iseki K. Intestinal ischemia-reperfusion increases efflux for uric acid via paracellular route in the intestine, but decreases that via transcellular route mediated by BCRP. J Pharm Pharm Sci, 15(2), 295-304, 2012.
  • Kobayashi M, Hidaka K, Chisaki I, Takahashi N, Ogura J, Itagaki S, Hirano T, Yamaguchi H, Iseki K. Effects of acidification and alkalinization agent on statins-induced muscle toxicity. Yakugaku Zasshi, 132(5), 609-615, 2012.
  • Takahashi N, Kobayashi M, Itagaki S, Hirano T, Takekuma Y, Sugawara M, Iseki K. Basic investigation for classification of anticancer drugs by pharmacological effects. Yakugaku Zasshi, 132(6), 777-783, 2012.
  • Ito H, Yamaguchi H, Fujikawa A, Tanaka N, Furugen A, Miyamori K, Takahashi N, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. J Pharm Biomed Anal, 71, 99-103, 2012.
  • Ogura J, Terada Y, Tsujimoto T, Koizumi T, Kuwayama K, Maruyama H, Fujikawa A, Takaya A, Kobayashi M, Itagaki S, Takahashi N, Hirano T, Yamaguchi H, Iseki K. The decrease in farnesoid X receptor, pregnane X receptor and constitutive androstane receptor in the liver after intestinal ischemia-reperfusion. J Pharm Pharm Sci, 15(5), 616-631, 2012.

2011年

  • Sato Y, Itagaki S, Kurokawa T, Ogura J, Kobayashi M, Hirano T, Sugawara M, Iseki K. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. Int J Pharm, (403), 136-138, 2011.
  • Furugen A, Yamaguchi H, Tanaka N, Ito H, Miyamori K, Fujikawa A, Takahashi N, Ogura J, Kobayashi M, Yamada T, Mano N, Iseki K. Quantification of intracellular and extracellular prostanoids stimulated by A23187 by liquid chromatography/electrospray ionization tandem mass spectrometry.  J. Chromatogr B Analyt　Technol Biomed Life Sci, (879), 3378-3385, 2011.
  • Furugen A, Kobayashi M, Narumi K, Watanabe M, Otake S, Itagaki S, Iseki K. AMP-activated protein kinase regulates the expression of monocarboxylate transporter 4 in skeletal muscle. Life Sci (88), 163-168, 2011.
  • Ogura J, Fujikawa A, Maruyama H, Kobayashi M, Itagaki S, Iseki K. Alteration of P-gp expression after intestinal ischemia-reperfusion following 16-h fasting. YAKUGAKU ZASSHI(131), 453-462, 2011.
  • Sato Y, Kobayashi M, Itagaki S, Hirano T, Noda T, Mizuno S, Sugawara M, Iseki K. Protective effect of lutein after ischemia-reperfusion in the small intestine. Food Chem(127), 893-898, 2011.
  • Kobayashi M, Gouda K, Chisaki I, Ochiai M, Itagaki S, Iseki K. Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol, 662, 9-14, 2011.
  • Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, Iseki K, Takeda Y, Yamada K. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull, 433-435, 2011.
  • Sato Y, Kobayashi M, Itagaki S, Hirano T, Noda T, Mizuno S, Sugawara M, Iseki K. Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein.  Biopharm Drug Dispos, 32(3), 151-158, 2011.
  • Sato Y, Itagaki S, Oikawa S, Ogura J, Kobayashi M, Hirano T, Sugawara M, Iseki K. Protective effect of soy isoflavone genistein on ischemia-reperfusion in the rat small intestine. Biol Pharm Bull, (34), 1448-54, 2011.
  • Shibayama Y, Iwashita Y, Yoshikawa Y, Kondo T, Ikeda R, Takeda Y, Osada T, Sugawara M, Yamada K, Iseki K. Effect of 5-Fluorouracil Treatment on SN-38 Absorption from Intestine in Rats. Biol Pharm Bull, 34(9), 1418-1415, 2011.
  • 齋藤佳敬，山田武宏，竹内　裕，笠師久美子，井関健. ファブチンによるワルファリンの代謝誘導が疑われた1例. 医療薬学(37), 345－350, 2011.
  • 川岸亨，熊井正貴，大崎由美子，新里里香，清川真美，原田幸子，笠師久美子，深井敏隆，山田武宏，井関　健. 汎用データベースソフトを用いた持参薬識別システムの構築と有用性の検討． 医薬品情報学,13, 103-112, 2011.

2010年

  • Itagaki S, Oikawa S, Ogura J, Kobayashi M, Hirano T, Iseki K.  Protective effects of rutin on ischemia-reperfusion injury in rat small intestine.  Food Chem, 118(2), 426-429, 2010.
  • Itagaki S, Ochiai A, Kobayashi M, Sugawara M, Hirano T, Iseki K.  Grapefruit juice enhance the uptake of coenzyme Q10 in the human intestinal cell-line Caco-2.  Food Chem, 120(2), 552-555,  2010.
  • Ogura J, Maruyama H, Kobayashi M, Itagaki S, Iseki K.  Pharmacokinetics of oral and intravenous administration of digoxin after intestinal ischemia-reperfusion.  Biol Pharm Bull, 33(5), 922-926, 2010.
  • 吉田和幸, 林紘司, 土居由有子, 大谷喜一, 井関健.  保険薬局を対象とした調剤過誤管理システムPREM-Sの開発. 医療薬学36巻1号, p1-9, 2010.
  • 斎藤　由起子, 平野　剛,　沖　洋充, 笠師　久美子, 菅原　満, 小林　正紀, 高橋　夏子,板垣　史郎, 井関　健.  In vitro実験系による肺がん化学療法レジメンの抗腫瘍効果の評価. 医療薬学36巻4号, 220-226, 2010.
  • Narumi K, Furugen A, Kobayashi M, Otake S, Itagaki S, Iseki K.  Regulation of human monocarboxylate transporters 1 in skeletal muscle cells by intracellular signaling pathways.  Biol Pharm Bull, 33(9), 1568-1573, 2010.
  • 板垣　史郎，中田　千絵，平野　剛，鷹野　瑠美，笠師　久美子，菅原　満，小林　正紀，井関　健. 放射線治療に伴う口腔粘膜障害発症の予防・軽減に関する研究. 医療薬学36巻9号, 696-702, 2010.
  • 林 えり子, 小林 正紀, 高橋 夏子, 平野 剛, 板垣 郎, 山田 武宏, 井関 健. In vitro実験系によるFOLFIRI療法およびmFOLFOX6療法レジメンの有効性およびEGFR発現変動の評価. 医療薬学36巻12号, 855-862, 2010.

2009年

  • Yasuda S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Differences between T47D cells and BeWo cells in the response of the ABCG2 promoter to sex hormone treatment.  Mol Biol Rep, 36(7), 1889-1896, 2009.
  • Itagaki S, Kurokawa T, Nakata C, Saito Y, Kobayashi M, Hirano T, Iseki K.  In vitro and in vivo antioxidant properties of ferulic acid: A comparative study with other natural oxidation inhibitors.  Food Chem, 114(2), 466-471, 2009.
  • Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim Biophys Acta, 1788(5), 911-917, 2009.
  • Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.  Biochim Biophys Acta, 1788(11), 2396-2403, 2009.
  • Yoshioka C, Yasuda S, Kimura F, Kobayashi M, Itagaki S, Hirano T, Iseki K. Expression and role of SNAT3 in the placenta.  Placenta, 30(12), 1071-1077, 2009.
  • 鷹野　瑠美，平野　剛，中田　千絵，笠師　久美子，菅原　満，小林　正紀，板垣　史郎，井関　健. がん化学療法に伴う口内炎の予防・改善に有効な抗酸化物質の探索. 医療薬学, 35(4): 247-253, 2009.
  • 久保田康生, 小林正紀, 笠師久美子, 高畑むつみ, 菅原満, 橋野聡, 井関健.  多発性骨髄腫における同種造血幹細胞移植後の慢性消化管GVHDに対しベクロメタゾン腸溶性製剤を投与した症例.  医療薬学35巻3号, 213-218, 2009.
  • 矢野育子, 井関健, 東海林徹, 青山隆夫, 木津純子, 中村均, 藤井俊志, 渡邊美智留, 野田幸裕, 脇屋義文, 森田邦彦, 手嶋大輔, 二神幸次郎. 薬学実務家教員の実態に関する調査研究.  医療薬学35巻1号, 43-49, 2009.
  • 山崎浩二郎，武隈　洋，西村あや子，宮本剛典，菅原　満，　井関　健.  高度腎機能障害患者におけるリネゾリドの体内動態. TDM研究, 26(4), 137-141, 2009.
  • 野田敏宏,高市和之,中村峰夫,唐澤豪貴,岡本泰範，栗原智仁，牧野利明,平野　剛,井関　健. 予防薬学を志向した保険薬局からの研究発信.  YAKUGAKU ZASHHI, 129(12), 1469-1473, 2009.

2008年

  • Hirano T, Yasuda S, Osaka Y, Asari M, Kobayashi M, Itagaki S, Iseki K. The inhibitory effects of fluoroquinolones on L -carnitine transport in placental cell line BeWo.  Int J Pharm, 351(1-2), 113-118, 2008.
  • Itagaki S, Chiba M, Kobayashi M, Sugawara M, Kobayashi M, Hirano T, Iseki K. Functional analysis of phenolsulfonphthalein transport system in Long-Evans Cinnamon rats. Biochim Biophys Acta, 1778(1), 270-275, 2008.
  • Kobayashi M, Kagawa T, Narumi K, Itagaki S, Hirano T, Iseki K. Bicarbonate supplementation as a preventive way in statins-induced muscle damage. J Pharm Pharmacol Sci, 11(1), 1-8,  2008.
  • Itagaki S, Chiba M, Kobayashi M, Hirano T, Iseki K. Contribution of multidrug resistance-associated protein 2 to secretory intestinal transport of organic anions.  Biol Pharm Bull, 31(1), 146-148, 2008.
  • Sembongi K, Tanaka M, Sakurada K, Kobayashi M, Itagaki S, Hirano T, Iseki K. A new method for determination of both thalidomide enantiomers using high-performance liquid chromatography systems. Biol Pharm Bull, 31(3), 497-500, 2008.
  • Yasuda S, Hasui S, Kobayashi M, Itagaki S, Hirano T, Iseki K. The Mechanism of carrier-mediated transport of folates in BeWo cells: The involvement of heme carrier protein 1 in placental folate transport. Biosci Biotechnol Biochem, 72(2), 329-334, 2008.
  • Ogura J, Kobayashi M, Itagaki S, Hirano T, Iseki K. Post-transcriptional regulation of breast cancer resistance protein after intestinal ischemia-reperfusion.  Biol Pharm Bull, 31(5), 1032-1035, 2008.
  • Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, Hirano T, Iseki K. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci, 82(17-18), 969-975, 2008.
  • Ogura J, Kobayashi M, Itagaki S, Hirano T, Iseki K.  Alteration of Mrp2 and P-gp expressions, including expression in remote organs, after intestinal ischemia-reperfusion. Life Sci, 82(25-26), 1242-1248, 2008.
  • Seki S, Itagaki S, Kobayashi M, Hirano T, Iseki K. Amiodarone increases the accumulation of DEA in a human alveolar epithelialum-derived cell line.  Biol Pharm Bull, 31(7), 1449-1452, 2008.
  • Itagaki S, Ochiai A, Kobayashi M, Sugawara M, Hirano T, Iseki K. Interaction of Coenzyme Q10 with the intestinal drug transporter P-glycoprotein.  J Agric Food Chem, 56(16), 6923-6927, 2008.
  • Yasuda S, Hasui S, Yamamoto C, Yoshioka C, Kobayashi M, Itagaki S, Hirano T, Iseki K. Placental folate transport during pregnancy. Biosci Biotechnol Biochem, 72(9), 2277-2284, 2008.
  • Obana A, Hiramitsu T, Gohto Y, Ohira A, Mizuno S, Hirano T, Bernstein PS, Fujii H, Iseki K, Tanito M, Hotta Y. Macular carotenoid levels of normal subjects and age-related maculopathy patients in a Japanese population.  Ophthalmology, 115(1), 147-157, 2008.

2007年

  • Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol, 557 (1), 1-8,  2007.
  • 久保田康生，中里恭子，須田範行，沖　洋充，菅原　満，　小林道也，齊藤浩司，井関　健. 外来化学療法における服薬指導の充実のための病棟－外来間連携ツールの構築. 医療薬学, 33(2), 152-158, 2007.
  • Kobayashi M, Kaido F, Kagawa T, Narumi K, Itagaki S, Hirano T, Iseki K.  Bicarbonate suppresses cerivastatin-induced apoptosis in human myocytes.  Int J Pharm, 341(1-2), 181-188, 2007.
  • Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K.  Improvement in Intestinal Coenzyme Q10 Absorption by Food Intake. Yakugaku Zasshi, 127(8), 1251-1254, 2007.
  • Kobayashi M, Kagawa T, Takano R, Itagaki S, Hirano T, Iseki K. Effect of medium pH on the cytotoxicity of hydrophilic statins. J Pharm Pharmacol Sci, 10(3), 332-9, 2007.
  • Chiba M, Itagaki S, Kobayashi M, Hirano T, Iseki K. Characterization of hepatobiliary organic anion transporters in Long-Evans Cinnamon rats. Drug Metab Pharmacokinet, 22(5), 387-390, 2007.
  • Kimoto E, Seki S, Itagaki S, Matsuura M, Kobayashi M, Hirano T, Goto Y, Tadano K, Iseki K. Efflux of N-monodesethylamiodarone by a thyroid hormone-sensitive transporter in the small intestine.  Drug Metab Pharmacokinet, 22(4), 307-312, 2007.
  • Noguchi M, Suzuki T, Kabayama K, Takahashi H, Chiba H, Shiratori M, Abe S, Watanabe A, Satoh M, Hasegawa T, Tagami S, Ishii A, Saitoh M, Kaneko M, Iseki K, Igarashi Y, Inokuchi J. GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Sci, 98(10), 1625-1632, 2007.
  • Katayama T, Nakanishi K, Nishihara H, Kamiyama N, Nakagawa T, Kamiyama T, Iseki K, Tanaka S, Todo S. Type I interferon prolongs cell cycle progression via p21WAF1/CIP1 induction in human colon cancer cells. Int J Oncol, 31(3), 613-620, 2007.
  • Chiba M, Itagaki S, Kobayashi M, Hirano T,  Iseki K.  Down-regulation of intestinal multidrug resistance-associated protein 2 in Long-Evans Cinnamon rats. Drug Metab Pharmacokinet, 22 (6), 450-455, 2007.
  • 井関健, 飯島康典, 池田俊也, 大谷道輝, 木平健治, 後藤伸之, 佐々木忠徳, 中村敏明, 藤田義人, 松山賢治, 柳川忠二. 後発医薬品に関する調査研究. 日本病院薬剤師会雑誌43巻8号, 1016-1018, 2007.
  • 宮本剛典, 齋藤佳敬, 井関健. 抗生物質の使用状況　北海道大学病院における抗生物質の使用状況. 化学療法の領域(23):3,  455-460, 2007.

2006年

  • Saito Y, Itagaki S, Kubo S, Kobayashi M, Hirano T, Iseki K. Purification by p-aminobenzoic acid (PABA)-affinity chromatography and the functional reconstitution of the nateglinide/H+ cotransport system in the rat intestinal brush-border membrane.  Biochem Biophys Res Commun, 340, 879-886, 2006.
  • Kamiyama N, Takagi S, Yamamoto C, Kudo T, Nakagawa T, Takahashi M, Nakanishi K, Takahashi H, Todo S, Iseki K. Expression of ABC Transporter in Human Hepatocyte Carcinoma Cells with Cross-resistance to Epirubicin and Mitoxantorone. AntiCancer Res, 26, 885-888, 2006.
  • Jin XH, Ohgami K, Shiratori K, Suzuki Y, Hirano T, Koyama Y, Yoshida K, Ilieva I, Iseki K, Ohno S. Inhibitory Effects of lutein on Endotoxin-Induced Uveitis in Lewis Rats. Invest Ophthalmology & Visual Sci, 47(6), 2562-2568, 2006.
  • Ogura W, Itagaki S, Kurokawa T, Noda T, Hirano T, Mizuno S, Iseki K. Protective Effect of Lutein on Ischemia-Reperfusion Injury in Rat Small Intestine. Biol Pharm Bull, 29(8), 1764-1766, 2006.
  • Kobayashi M, Otsuka Y, Itagaki S, Hirano T, Iseki K. Inhibitory effects of statins on human monocarboxylate transporter 4. Int J Pharmaceu, 317, 19-25, 2006.
  • 久保田康生，沖　洋充，山崎浩一，菅原　満，　西村正治，井関　健. 患者の健康食品摂取状況および意識調査と健康食品データベース構築. 日本病院薬剤師会雑誌，42(7), 927-929, 2006.
  • 金内美妃, 澤口利香, 郡修徳, 千本木要, 坂井英夫, 浅野真, 井関健. 院内製剤としてのケタミン製剤の臨床応用に関する評価　経口または口腔内投与後のケタミン,ノルケタミンの血漿中濃度プロファイル解析. 日本ペインクリニック学会誌, 13:(1), 18-22, 2006.
  • 金内美妃, 浅野真, 郡修徳, 千本木要, 坂井英夫, 井関健. ケタミン寒天製剤の神経因性疼痛患者における使用経験　鎮痛効果と血漿中濃度. 日本ペインクリニック学会誌1):(1), 8p-12p, 2006.
  • Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/beta mipron in critically ill patients receiving continuous renal replacement therapy: a pilot study. ASAIO J. 52(4), 398-403, 2006.
  • Hirano T, Yasuda S, Osaka Y, Kobayashi M, Itagaki S, Iseki K. Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. Biochim Biophys Acta, 1758, 1743-1750, 2006.
  • Yasuda S, Itagaki S, Hirano T, Iseki K. Inductive effect of estrogen on ABCG2 expression in the placental cell line BeWo. J Pharm Pharmaceut Sci, 9 (1), 133-139, 2006.
  • Itagaki S, Ogura W, Sato Y, Noda T, Hirano T, Mizuno S, Iseki K. Characterization of the disposition of lutein after i.v. administration in rats. Biol Pharm Bull, 29 (10),  2123-2125,  2006.
  • Kurokawa T, Itagaki S, Yamaji T, Nakata C, Noda T, Hirano T, Iseki K. Antioxidant activity of a novel extract from Bamboo grass (AHSS) against Ischemia-Reperfusion injury in rat small intestine. Biol Pharm Bull, 29 (11), 2301-2303, 2006.

2005年

  • Itagaki S, Saito Y, Kubo S, Otsuka Y, Yamamoto Y, Kobayashi M, Hirano T, Iseki K. H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine. J Pharmacol Exp Ther, 312, 77-82, 2005.
  • Itagaki S, Otsuka Y, Kubo S, Okumura H, Saito Y, Kobayashi M, Hirano T, Iseki K. Intestinal uptake of nateglinide by asn intestinal fluorescein transporter.  Biochim Biophys Acta, 1668, 190-194, 2005.
  • Kikuchi T, Suzuki M, Kusai A, Iseki K, Sasaki H. Synergistic effect of EDTA and boric acid on corneal penetration of CS-088. Int J Pharm, 290, 83-89, 2005.
  • Kikuchi T, Ito N, Suzuki M, Kusai A, Iseki K, Sasaki H. Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent.  Int J Pharm, 299, 100-106, 2005.
  • Kikuchi T, Suzuki M, Kusai A, Iseki K, Sasaki H, Nakashima K. Mechanism of permeability-enhancing effect of EDTA and boric acid on the corneal penetration of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088),  Int J Pharm, 299, 107-114, 2005.
  • Itagaki S, Chiba M, Shimamoto S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. Characterization of secretory intestinal transport of phenolsulfonphthalein. Drug Metab Pharmacokinet, 20(1), 72-78, 2005.
  • Itoh T, Itagaki S, Sumi Y, Hirano T, Takemoto I, Iseki K. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemother Pharmacol, 55, 420-424, 2005.
  • Itagaki S, Sumi Y, Shimamoto S, Itoh T, Hirano T, Takemoto I, Iseki K. Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue. Cancer Chemother Pharmacol. 55, 502-506, 2005.
  • Itagaki S, Kobayashi Y, Otsuka Y, Kubo S, Kobayashi M, Hirano T, Iseki K. Food-drug interaction between ferulic acid and nateglinide involving the fluorescein/H+ cotransport system. J Agric Food Chem. 53(7), 2499-2502, 2005.
  • Kobayashi M, Saito Y, Itagaki S, Hirano T, Iseki K. Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane. Biochim Biophys Acta. 1715, 19-24, 2005.
  • 牧野敏明、中村峰夫、野田敏宏、高市和之、井関　健. コエンザイムQ10含有健康食品における成分含量と溶解性 医療薬学, 31(7), 505-510, 2005.
  • Itagaki S, Shimamoto S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. Phenolsulfonphthalein transport by potential-sensitive urate transport system. Eur J Pharmacol, 518, 83-89, 2005.
  • Saito Y, Itagaki S, Otsuka Y, Kobayashi Y, Okumura H, Kobayashi M, Hirano T, Iseki K. Substrate specificity of nateglinide/H+ cotransport system for phenolic acids J Agric Food Chem, 53, 6100-6104, 2005.
  • Kobayashi M, Fujita I, Itagaki S, Hirano T, Iseki K. Transport Mechanism for L-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells).   Biol Pharm Bull, 28(7), 1197-1201, 2005.
  • 日向真知子、平田章二、井関　健、金内美妃、郡　修徳. 含嗽コンプライアンスの向上を目的としたアムホテリシンB含嗽液の試作 逓信医学, 57(3), 163-171, 2005.
  • 金内美妃，郡　修徳，千本木要，坂井英夫，井関　健. 調製法の簡便さと服用性の向上を目指した院内製剤としての経口ケタミン製剤の調製と評価(1)-寒天を用いた製剤の検討-. 薬学雑誌, 125(2), 187-196, 2005.
  • Takemoto I, Itagaki S, Chiba M, Itoh T, Hirano T, Iseki K. Characterization of secretory intestinal transport of the lactone form of CPT-11. Cancer Chemother Pharmacol, 129-133, 2005.
  • Yasuda S, Itagaki S, Hirano T, Iseki K. Expression Level o ABCG2 in the Placenta Decreases from the Mid Stage to the End of Gestation. Biosci Biotechnol Biochem, 69(10), 1871-1876, 2005.
  • Goto Y, Itagaki S, Umeda S, Kobayashi M, Hirano T, Iseki K, Tadano K. Transepithelial Transport of Telmisartan in Caco-2 Monolayers. Biol Pharm Bull, 28(12), 2235-2239, 2005.

2004年

  • Itoh T, Takemoto I, Itagaki S, Sasaki K, Hirano T, Iseki K. Biliary excretion of irinitecan and its metabolites. J Pharm Pharmacol Sci, 7(1), 13-18, 2004.
  • Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. Comparison of the disposition behavior of organic anions in an animal model for Wilson's Disease (Long-Evans Cinnamon rats) with that in normal Long-Evans Agouti rats. Drug Metab Pharmacokinet, 19(2), 150-154, 2004.
  • Itagaki S, Shimamoto S, Hirano T, Iseki K, Sugawara M, Nishimura S, Fujimoto M, Kobayashi M, Miyazaki K. Comparison of urinary excretion of phenolsulfonphthalein in animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: Inprovement of primary active organic anion transporter. J Pharm Pharmacol Sci, 7(2), 235-242, 2004.
  • Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats. J Pharm Pharmacol, 56, 809-812, 2004.
  • Kobayashi M, Itagaki S, Hirano T, Iseki K. Mechanism of L-lactic acid transport in L6 skeletal muscle cells. Drug Metab Pharmacokinet, 19(5), 363-368, 2004.
  • 金内美妃1),群　修徳1),　千本木要2),　坂井英夫3),　浅野　真4),井関　健5);1)北海道薬科大学臨床薬剤学分野,2)札幌逓信病院薬剤部,3)王子総合病院医療技術部薬剤科,4)王子総合病院　麻酔科,5)北海道大学大学院薬学研究科臨床薬剤学分野. 神経因性疼痛に対する鎮痛薬としての経口ケタミンゲル製剤の調製と評価. PHARM TECH JAPAN, 20(12), 133-138, 2004.

2003年

  • Itagaki S, Sugawara M, Kobayashi M, Nishimura S, Fujimoto M, Miyazaki K, Iseki K. Major role of organic anion transporters in the uptake of phenoldulfonphtalein in the kidney. Eur J Pharmacol, 475, 85-92, 2003.
  • Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. Mechanism of active sevretion of phaenolsulfonphthalein in the liver via Mrp2(abcc2), an organic anion transporter. Drug Metab Pharmacokinet, 18(4), 238-244, 2003.
  • Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K. Pharamcokinetics and the nost suitable dosing regimen of fluvonazole in clinically ill patients receiving continuous hemodiafiltration. Intensive Care Med, 29(10), 1844-1848, 2003.
  • Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hiorano T, Iseki K. Pharamcokinetics  of teicoplanin in clinically ill patients undergoing continuous hemodiafiltration. Intensive Care Med, 29(9), 2094-2095, 2003.
  • 矢ヶ崎和明、丸藤　哲、伊藤靖子、松田直之、亀上　隆、平野　剛、井関　健. 持続的血液濾過透析患者におけるバンコマイシンの薬物動態解析. 日本救急医学会雑誌, 14(11), 739-744, 2003.